(...) Regarding the specific success rates, the phase III MARINA and ANCHOR trials for ranibizumab, another Anti-VEGF agent used in AMD, showed that 90–95% of patients achieved stabilization (defined as losing < 15 letters on the visual acuity chart) over 1 to 2 years of monthly treatment. The gene discussed is VEGFA; the disease is age-related macular degeneration.